Drug Database
Back to search

France· FR:60462659

LAMIVUDINE/ZIDOVUDINE ARROW 150 mg/300 mg, comprimé pelliculé sécable

A zidovudine and lamivudine product containing zidovudine + lamivudine, registered in France by ARROW GENERIQUES, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC J05AR01

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedLAMIVUDINE/ZIDOVUDINE ARROW 150 mg/30…ATCJ05AR01REGISTER NO.FR:60462659PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about zidovudine + lamivudineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Zidovudine and lamivudine is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AR01 (zidovudine and lamivudine), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search zidovudine and lamivudine products by name

Zidovudine and lamivudine · ATC J05AR01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ZIDOVUDINE + LAMIVUDINE
Manufacturer
ARROW GENERIQUES
Country
France (FR)
ATC code
J05AR01
ATC class
Zidovudine and lamivudine
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930082812
    plaquette(s) PVC PVDC aluminium de 60 comprimé(s)
    EUR 132.26

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for zidovudine and lamivudine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check zidovudine and lamivudine against other medicinesHow interaction checks work

Zidovudine and lamivudine · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Zidovudine and lamivudine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All zidovudine and lamivudine products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Belgium · Lamivudine/Zidovudine Viatris
  • Cyprus · Lamivudine/Zidovudine Aurobindo
  • Germany · Lamivudin/Zidovudin, Lamivudin/Zidovudin Accord
  • United Kingdom (Northern Ireland) · Lamivudine/Zidovudine Milpharm, Lamivudine/Zidovudine Mylan
  • Iceland · Combivir
  • Italy · Lamivudina E Zidovudina Aurobindo, Lamivudina E Zidovudina Mylan
  • Liechtenstein · Combivir
  • Luxembourg · Lamivudine/Zidovudine Viatris
  • Malta · Lamivudine/Zidovudine Mylan
  • Netherlands · Lamivudine/Zidovudine Aurobindo, Lamivudine/Zidovudine Viatris
  • Norway · Combivir
  • Portugal · Lamivudina + Zidovudina Accord, Lamivudina + Zidovudina Aurobindo
  • Romania · Lamivudină/Zidovudină Aurobindo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eab915c3-e79c-430c-90ac-a07709229e3a
GET /v1/drugs/eab915c3-e79c-430c-90ac-a07709229e3a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "60462659",
  "date_amm": "2017-01-30",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "ZIDOVUDINE + LAMIVUDINE",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé sécable",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about zidovudine and lamivudine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console